The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
about
Acromegaly pathogenesis and treatmentGrowth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects.Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.Serum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Expert consensus document: A consensus on the medical treatment of acromegaly.A structural and functional acromegaly classificationGrowth hormone tumor histological subtypes predict response to surgical and medical therapy.Medical therapy of acromegalyIGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.The association between biochemical control and cardiovascular risk factors in acromegaly.SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyMonitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?Multiple facets in the control of acromegaly.What is active acromegaly and which parameters do we have?Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefitsClinical implications of growth hormone-secreting tumor subtypes.The changing face of acromegaly--advances in diagnosis and treatment.Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.Diagnosis of acromegaly: state of the art.Octreotide for acromegaly treatment: a reappraisal.Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta-analysis.Biochemical investigations in diagnosis and follow up of acromegaly.Current management practices for acromegaly: an international survey.Role of IGF1-(CA)19 promoter microsatellite in the clinical presentation of acromegaly.Acromegalic patients lost to follow-up: a pilot study.Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly.Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients.Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.Long-term changes in serum IGF-1 levels after successful surgical treatment of growth hormone-secreting pituitary adenoma.Diagnosis of acromegaly: black, white… and sometimes gray!Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients.Daily life reflections of acromegaly guidelines.Comparison of oral glucose tolerance test (OGTT) 100 g with OGTT 75 g for evaluation of acromegalic patients and the impact of gender on test reproducibilityInternational Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureUpdates in Diagnosis and Treatment of Acromegaly
P2860
Q24647360-09F157B3-9EDB-428C-983D-0B9AB2C8CCC2Q33739766-6815C330-5B9C-4E27-B448-9CECFAA4A0FFQ33794409-FA7659BC-BDC0-440D-976D-7804B3043670Q33817041-217505E7-7299-40A0-92C2-66553992E679Q34031906-FDD74DFE-DDD3-407F-AA4F-C713217B5A0CQ34406566-39A88F22-C888-473B-9874-34F2532688CDQ34810811-4F3906C3-FFEF-4A03-97E1-BB3804703366Q35091578-1B6D4775-79CA-4D4B-9815-4440805B42F9Q35895856-1690849C-2F32-4293-8815-1C68ECBCA6ADQ36202868-96085761-C5A6-46AB-8322-980B8579C8F6Q36303177-BFD45F85-D187-4B18-9F2B-61C37BBE5A9BQ36456312-04CD1DFC-F837-4437-8AAC-3366CD731DCDQ36845980-FB90B00A-B4FF-49CA-9346-335C517B41E4Q37531066-DC29B098-E7D1-4411-9FB9-B877DB91681AQ37977989-F5536344-29CA-447D-87D9-E24C557EB19BQ37980741-B0F7B854-FE6A-4E0D-A04A-952649126F08Q37995533-3B6D1C74-914A-42F5-B7C8-0969879989ABQ38021680-9CE30A3C-6D9A-4E9B-B40A-25A45F0BEF4DQ38062441-F3CED2D2-6D0B-4DE1-8CB1-1D409E31C118Q38131055-EAE7B6CC-8087-48D5-A437-B4DD34180E5EQ38152458-24495FE4-F0E3-4579-8F13-D647F81E7332Q38185306-43F7DAE3-B5B9-467C-A62C-9F5BD916A195Q38640384-ED9E53E8-C681-49AB-9F32-2941EB9DDA52Q38862772-5DB4A7E2-13D8-44EF-8FB6-3669D37EB05EQ39123579-D0C8A33B-D7F5-437D-99D3-9B78BD965FF4Q39818772-372BD1C9-D8EA-4F5D-BC35-3379C6B8AB4AQ42468096-82AE5828-095A-4A0F-A192-A5B8D00BB3F7Q43898221-8B76F9F1-3499-4101-B5A7-BF4658E6DE0CQ45891939-58F20C0D-394D-487B-AF2C-D0A32D045733Q45912383-A4E06374-DB52-407A-887F-C37C732643ECQ46335250-AEBF63AF-2C67-4FD7-A073-BCD2BFA97386Q48766407-9171FF5C-0D7B-4841-83D5-33F974ED39E6Q50884057-03E70F59-97E6-4E0B-B4CE-0B5A40476B00Q50944176-138E4B37-AE88-48FE-A60C-83DC0170F119Q51257686-CD5515F6-6190-48E9-891E-B8C201EB3DE4Q51271616-7B5D04FF-C454-4881-BEFD-501A9A86D59BQ53765411-F52936BF-8A5C-403D-A0C4-A92ECE49CDDEQ56962774-6E94E76B-5A16-476F-BA8D-C1EFA9725F78Q57144951-C5ED2CEA-7AC4-4960-8192-DABA28CDC92DQ57822729-CA933112-E335-4C98-9CF7-6E3904FB26CE
P2860
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The utility of oral glucose to ...... 166 patients with acromegaly.
@en
The utility of oral glucose to ...... 166 patients with acromegaly.
@nl
type
label
The utility of oral glucose to ...... 166 patients with acromegaly.
@en
The utility of oral glucose to ...... 166 patients with acromegaly.
@nl
prefLabel
The utility of oral glucose to ...... 166 patients with acromegaly.
@en
The utility of oral glucose to ...... 166 patients with acromegaly.
@nl
P2093
P356
P1476
The utility of oral glucose to ...... 166 patients with acromegaly.
@en
P2093
James M Mirocha
John D Carmichael
Shlomo Melmed
Vivien S Bonert
P304
P356
10.1210/JC.2008-1371
P407
P577
2008-11-25T00:00:00Z